New early-onset Alzheimer’s data show that lecanemab can slow functional decline—even while tau continues to spread in the brain. The research helps explain how amyloid-lowering treatments may still preserve daily life, despite the disease’s complexity.
In a one-hour seminar, a leading neurologist answers the most important questions families ask about what these new therapies can realistically deliver — from effectiveness and safety to eligibility, infusion logistics, cost, and access.
New evidence suggests genetics—not geography—may explain why Leqembi causes fewer ARIA brain side effects in parts of Asia, and what that means for families everywhere.
Alzheimer’s treatment eligibility may be far larger than previously thought. A major Nature study using blood tests suggests millions more older adults could qualify for treatment than current use reflects. As diagnosis becomes easier, demand for drugs like Leqembi could shift sharply.
New studies highlight smoother tolerability, easier routines, and practical safety updates that make the rivastigmine patch an increasingly caregiver-friendly option.
Three major GLP-1 trials came out in late 2025. One weight-loss drug slowed early Alzheimer’s decline, while two others failed. Surprisingly, this mixed pattern may point the way toward a promising new treatment direction.
New long-term data suggests lecanemab could delay the shift from mild memory loss to moderate Alzheimer’s by up to eight years—offering families precious time and renewed hope.
Leqembi is one of the first Alzheimer’s treatments proven to slow decline. A new MRI study helps explain what it can—and cannot—do in the brain’s early months, offering clearer expectations for caregivers.
NEW RESEARCH: A diabetes medication already helping millions, called Jardiance, improves memory, strengthens blood flow, and supports overall brain health in pre- and early Alzheimer’s.
Some everyday medicines may nudge dementia risk higher — but safer, equally effective alternatives often exist. Here’s how to replace high-risk drugs with brain-friendlier options
People with dementia who were consistently seen by the same General Practitioner (GP) are given fewer medicines and are less likely to be given medicines that can cause problems, according to researchers at University of Exeter. Learn more.
New early-onset Alzheimer’s data show that lecanemab can slow functional decline—even while tau continues to spread in the brain. The research helps explain how amyloid-lowering treatments may still preserve daily life, despite the disease’s complexity.
A deep promise to be there for an Alzheimer’s parent, this heartwarming song was written as a tribute to families facing dementia.
People with dementia who were consistently seen by the same General Practitioner (GP) are given fewer medicines and are less likely to be given medicines that can cause problems, according to researchers at University of Exeter. Learn more.
A deep promise to be there for an Alzheimer’s parent, this heartwarming song was written as a tribute to families facing dementia.
Amyloid is one of the leading culprits behind Alzheimer’s. Scientists know it damages memory by killing brain cells. Now research reveals how amyloid triggers memory loss in perfectly healthy brain cells as well. Learn more about how Alzheimer’s develops.
Getting out into the fresh air and taking a walk does good things for your brain and well-being, researchers say.
No spam, only news and updates.
